VIATRIS INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - VIATRIS INC
Explicit Guidance:
- 2027 Revenue & Growth: Revenue expected to remain flat in 2027 compared to 2026 levels, driven by the assumption that the Nashik facility will not contribute to revenue growth in 2027 due to the ramp-up delay.
- 2027 Earnings & Margins: Midpoint of adjusted EBITDA guidance revised upward to $4.5 billion; gross margins and EBITDA margins expected to expand despite the return of lower-margin OSD products from Nashik, due to offsetting growth in US complex generics, China, and Pasira acquisition.
- Capital Allocation: Commitment to a 50/50 split over the next 4–5 years (through 2030) between shareholder returns (dividends and buybacks) and Business Development, totaling $10–12 billion.
- Leverage: Target leverage ratio remains at 2.9x, staying below the long-term midpoint of 2.8–3.2x despite the Pacera transaction.
Business-Segment Outlook:
- China: Projecting low-to-mid single-digit year-over-year growth in 2027 (down from 15–17% in H1 2026 and 10% in Q3), with Q4 expected to show mid-to-high single-digit growth. First-half 2027 growth anticipated despite difficult comps, though likely slower than the second half.
- US Complex Generics: Transdermal Estradiol segment expected to sustain 70% year-over-year market growth, with the company's business in this area having doubled over the past year; supply constraints are being addressed via third-party packagers and a second packaging line at the Vermont plant.
- Product Launches:
- Meloxicam: Awaiting PDUFA decision on December 27, 2027; launch expected in 2027 with a target to achieve rapid market adoption.
- Pacera Assets: Acquisition of Exemestane (Expro) and Zolletta expected to drive high-margin, US-focused growth through 2030.
- Pasira: Contribution to margins expected as assets come online, supporting overall margin expansion.
- China Channel Shift: Continued pivot from hospital to retail/e-commerce, with e-commerce growth running at 30–40% year-over-year (currently 10–15% of the business).
Market and Competitive Outlook:
- Estradiol Market: Driven by removal of black box warnings on HRT and increased utilization of GLP-1 compounds causing oral absorption issues, fueling a shift toward transdermal delivery.
- Patent Landscape (Expro): Expectation to extend exclusivity volume limitations through settlement with Fresenius in 2030, with active efforts to push additional generic entry closer to the mid-2030s.
- Competition: Fast-acting Meloxicam positioned as highly differentiated with strong opioid-sparing data compared to competitors like Journavax and steroid-based options.
- Supply Chain: Nashik facility (25th in network, low-margin OSD) is a bottleneck for specific emerging market ARV products, but its impact is being offset by higher-margin US and China growth.
Macro / Industry Outlook:
- China Demographics: Strong tailwinds from an aging, retired population with disposable income seeking branded, high-quality medication over local generics.
- Regulatory Environment: China policy environment remains complex with provincial execution variances, causing a moderation in growth compared to H1 2026.
- US Healthcare Trends: Structural shift in hormone replacement therapy utilization and the physiological impact of GLP-1 drugs driving demand for transdermal formats.
Strategic Initiatives:
- Nashik Facility Remediation: Plant shutdown for full remediation; target restart of production in January 2027, with full capacity recovery expected by end of Q1 or Q2 2027.
- Capacity Expansion: Adding a second packaging line at the Vermont plant by mid-to-end of 2027 to support Estradiol growth.
- Acquisition (Pacera Biosciences): Completed acquisition of in-market, high-margin US assets (Expro, Zolletta) to acquire commercial capabilities for Meloxicam launch and accelerate market access.
- Business Development: Ongoing "enterprise-wide review" to identify cost savings and new value-added products; continued focus on acquiring assets that are in-market, accretive, and US-focused.
- Cost Synergies: Pacera acquisition projected to achieve an unsynergized multiple of 9.3x, improving to 7.3x post-synergies; expected to have minimal leverage impact at year-end.
Risks and Headwinds to Outlook:
- Nashik Ramp-Up: Potential for delays in returning the plant to full operational capacity beyond early 2027; revenue lost in 2026 ($100M in Q3, $100M in Q4) will not be recouped in 2027.
- Regulatory Approval: Final FDA label negotiation for Meloxicam, specifically regarding "opioid-sparing" language, remains a variable.
- China Policy Volatility: Continued provincial-level policy execution differences and procurement pressures in the hospital channel (50% of China business).
- Supply Constraints: Current inability to meet unprecedented demand for transdermal estradiol products without third-party or additional internal capacity.
- Market Dynamics: Near-term slowdown in Expro growth due to market dynamics, though expected to accelerate with company resources.
Management Tone on the Future:
- Confidence Level: High confidence in 2027 momentum, citing "great momentum" heading into the next year despite headwinds.
- Strategic Pivot: Confident shift from OSD-based generics to a "complex portfolio" (injectables, transdermals, respiratory devices) offering "stickier revenue, higher margins, more predictability."
- Financial Discipline: Emphasis on "financially disciplined" M&A (Pacera) and capital allocation, balancing growth investments with shareholder returns.
- Offsetting Headwinds: Repeated assertion that growth in US complex generics, China, and Pasira "more than offset" the Nashik headwinds.
- Company
- VIATRIS INC
- Keywords
- VIATRIS INC